Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Capital Leases (2016 - 2018)

Ironwood Pharmaceuticals' Capital Leases history spans 9 years, with the latest figure at $158000.0 for Q4 2018.

  • For Q4 2018, Capital Leases changed N/A year-over-year to $158000.0; the TTM value through Dec 2018 reached $158000.0, changed N/A, while the annual FY2018 figure was $158000.0, N/A changed from the prior year.
  • Capital Leases for Q4 2018 was $158000.0 at Ironwood Pharmaceuticals, up from $21000.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $3.2 million in Q2 2014 and bottomed at $21000.0 in Q1 2017.
  • The 5-year median for Capital Leases is $687000.0 (2015), against an average of $1.3 million.
  • The largest annual shift saw Capital Leases soared 1494.95% in 2014 before it crashed 91.7% in 2017.
  • A 5-year view of Capital Leases shows it stood at $2.6 million in 2014, then plummeted by 88.1% to $306000.0 in 2015, then tumbled by 73.2% to $82000.0 in 2016, then crashed by 74.39% to $21000.0 in 2017, then surged by 652.38% to $158000.0 in 2018.
  • Per Business Quant, the three most recent readings for IRWD's Capital Leases are $158000.0 (Q4 2018), $21000.0 (Q1 2017), and $82000.0 (Q4 2016).